Discover MabDesign

MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.
carl-newton-2C6kAtCXf6U-unsplash

Access our network

Join the MabDesign network to take advantage of all the advantages and opportunities offered.
casey-horner-9vf1uj6i6Ww-unsplash

Develop your skills

Consult and register for our next training courses in order to acquire new expertise.
smartworks-coworking-Uz8THWPXwhI-unsplash

Explore our business services

The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.
arlington-research-kN_kViDchA0-unsplash

Upcoming events

Add your title here

27
Feb.
February 27-29, 2024
Partner Event
07
Mar.
Thursday, March 7, 2024, at 10:30 ET | 16:30 CET
Webinar
12
Mar.
12-15 March 2024
Partner Event
13
Mar.
March 13-14, 2024
Partner Event
18
Mar.
March 18-20, 2024
Partner Event
19
Mar.
March 19- 21, 2024
Partner Event

Our News

Gio Therapeutics logo

GIO Therapeutics - nouveau membre international

GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals.
vaccins innovation

Prophylactic or Therapeutic : what does the future hold for vaccines ?

Fuelled by decades of innovation, vaccines are an essential tool in the fight against disease. Historically focused on prophylaxis to prevent the spread of infectious diseases, new generations of vaccines are now being developed and/or are already available in other therapeutic areas including oncology. Historically focused on prophylaxis and infectious diseases, they are now opening up to new avenues of development, with a range of vaccine technologies, the positioning of vaccines as a new therapeutic tool, and the opening up of other therapeutic areas such as oncology.
mAbs, anticorps monoclonal monoclonaux

Monoclonal antibodies: the stars of therapeutic proteins

Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
OSIVAX-logo

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

OUR BOARD OF DIRECTORS